Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study
News-Medical carries a company announcement from Oncopeptides on early data from its ongoing open-label INSULA study at Oslo University Hospital. In the first three patients with recurrent glioblastoma, given melflufen before scheduled surgery, resected tumor tissue contained active compound, which the company says indicates blood-brain barrier penetration. No major drug-related toxicity was reported so far; enrolment continues toward approximately 10 patients.
Why it matters: Relevant to clinicians who refer patients with recurrent glioblastoma for surgery and who follow early-stage research on delivering drugs into brain tumors.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to news-medical.net. October 9, 2026.
